This article was originally published in The Gray Sheet
Recent management changes include departures of Thomas Frank, who has resigned as VP of corporate R&D, and Francis Griffin, VP of international development. Frank's position is being filled by Dennis Tomisake, director of R&D; Griffin's replacement has not been announced. In addition, Robert Durbin, chief financial officer, is retiring early as of Sept. 30. The firm says it expects to select a new CFO in September.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.